Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 457

Articles by Marisa Woutersen

LSPN Spring: Preliminary injunctions ‘a focal point’ in UPC decisions
Europe
LSPN Spring: Preliminary injunctions ‘a focal point’ in UPC decisions
A significant uptake in unitary patents show court is here “in a big way” | Speakers shed light on the UPC's approach to preliminary injunctions and evidence gathering at LSPN Spring in Boston.   9 May 2024
LSPN Spring: ‘Fascinating’ UPC is a ‘wake-up call’ for US lawyers
Unified Patent Court
LSPN Spring: ‘Fascinating’ UPC is a ‘wake-up call’ for US lawyers
10x Genomics injunction showed the need to take the court ‘really seriously’ says US lawyer | With a focus on efficiency and plaintiff-friendly measures, the UPC's impact on patent valuations and litigation strategies is becoming increasingly apparent, at LSPN Spring.   9 May 2024
Boston to host biggest LSPN North America–Spring Conference
Americas
Boston to host biggest LSPN North America–Spring Conference
Two-day event in Boston brings together leading in-house patent counsel | Regeneron, USPTO, the Broad Institute and Novartis among attendees I Agenda includes the UPC, patent strategies, and multijurisdictional patent litigation | Registrations for LSPN Fall now open.   7 May 2024
Biotech
BioNTech’s patent counsel on fostering groundbreaking innovation
Ahead of her panel discussion at LSPN North America, BioNTech’s patent counsel, shares insights into her role and ensuring innovations meet the criteria of novelty and nonobviousness.   2 May 2024
Biotech
CureVac and Acuitas wind up COVID-19 vaccine dispute
Settlement comes after Acuitas alleged CureVac deliberately omitted its scientists as inventors on four US patents related to COVID-19 vaccines, claiming co-inventorship | Patents in suit relate to ongoing litigation with Pfizer and BioNTech.   30 April 2024
Pharma
GSK settles HIV drug licensing dispute
GSK subsidiary and Exavir Therapeutics end dispute over licensing rights for HIV-drug compounds | Resolution follows allegations that Exavir's actions disrupted ViiV Healthcare's research collaboration with a US university.   25 April 2024
Biotech
US Supreme Court denies Vanda's bid to revive sleep drug patents
Vanda denied opportunity to revive patents for its sleep-disorder drug in dispute against Teva | Decision also rejects revisiting the 2007 case, KSR International v Teleflex, concerning the issue of obviousness in patent claims.   23 April 2024
Biotech
Moderna COVID-19 vaccine dispute halted by court
A US District Court has granted a motion to stay the company’s lawsuit against Pfizer and BioNTech | Decision pauses proceedings until two inter partes review proceedings are resolved.   16 April 2024
Pharma
FDA faces allegations over ‘capricious’ allergy drug approval
Endo and its subsidiary have challenged the FDA's approval of an application by BPI Labs and Belcher Pharmaceuticals | Dispute argues the FDA undermined regulatory frameworks and patent protection.   11 April 2024
MedTech
Microsoft prevails in 3D medical imaging tech dispute
The Federal Circuit upholds a ruling in favour of Microsoft against an Orlando tech company | Dispute concerned 3D medical imaging technology | Court affirms PTAB’s decision to invalidate most of the patent.   4 April 2024

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.